Please be aware that quinagolide tablets have been discontinued in the UK. The 25 microgram and 50 microgram strengths were discontinued in February 2026, and the 75 microgram strength has also been discontinued, with remaining stock expected to expire around December 2026.

Although relatively few patients are likely to be affected, this discontinuation may present significant challenges for patients with prolactinomas who have documented intolerance to ergot-derived dopamine agonists such as cabergoline or bromocriptine.

The DHSC medicines supply notification advises specialists not to initiate quinagolide and recommends that GP practices identify patients currently prescribed the medicine and seek specialist advice regarding ongoing management. Members should therefore anticipate requests for guidance from primary care colleagues.

Clinicians may wish to proactively review patients currently prescribed quinagolide and consider alternative treatment strategies where appropriate.